Guidance for healthcare professionals on how to administer molnupiravir in people who have difficulty swallowing capsules is available from .
All pharmacy professionals involved with supply of molnupiravir (Lagevrio®) must be aware of the statement in the SmPC that Lagevrio is not recommended during pregnancy.
The NHSE SOP for CMDUs states that all individuals of childbearing potential who are prescribed molnupiravir should be advised to use effective contraception for the duration of treatment and for 4 days after the last dose of molnupiravir.
Individuals are not required to take a pregnancy test before starting treatment. However, all healthcare professionals are asked to ensure that any patients who receive a COVID antiviral while pregnant are reported to the UKCOVID-19 antivirals in pregnancy registry on 0344 892 0909 so that they can be followed up.
For more information, go to bumps – best use of medicine in pregnancy.
It’s not known how much molnupiravir passes into breast milk.
The SmPC states that breastfeeding is not recommended during treatment with molnupiravir and for 4 days after the last dose.
An individual risk assessment should be conducted for each patient, taking into account the benefits of any treatment and the benefits of continued breastfeeding.
Further SPS information and advice on molnupiravir is available.
Typically, few patients are likely to read the Patient Information Leaflet so it is essential that they are provided with key information at every interaction with a healthcare professional.
Patients can also be referred to further NHS sources of information: